REGENXBIO to Participate in Upcoming Investor Conferences

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) has announced its participation in five major investor conferences during March and April 2025. The company will engage in fireside chat presentations at:

• TD Cowen's 45th Annual Health Care Conference in Boston (March 5, 1:10pm ET)
• Leerink Partners Global Healthcare Conference in Miami (March 11, 9:20am ET)
• Barclays 27th Annual Global Healthcare Conference in Miami (March 12, 3:30pm ET)
• UBS Virtual CNS Day (March 17, 10:00am ET)
• RBC Inaugural Virtual Ophthalmology Conference (April 3, 8:15am ET)

Select fireside chats will be available via live webcast through REGENXBIO's website, with recordings accessible for approximately 30 days after each presentation.

News Market Reaction – RGNX

-0.74%

1 alert

-0.74% News Effect

On the day this news was published, RGNX declined 0.74%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

ROCKVILLE, Md., Feb. 25, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

TD Cowen's 45th Annual Health Care Conference
Fireside Chat: Wednesday, March 5 at 1:10pm ET
Location: Boston, MA

Leerink Partners Global Healthcare Conference
Fireside Chat: Tuesday, March 11 at 9:20am ET
Location: Miami, FL

Barclays 27^th Annual Global Healthcare Conference 
Fireside Chat: Wednesday, March 12 at 3:30pm ET
Location: Miami, FL

UBS Virtual CNS Day
Fireside Chat: Monday, March 17 at 10:00am ET
Location: Virtual

RBC Inaugural Virtual Ophthalmology Conference 
Fireside Chat: April 3 at 8:15am ET
Location: Virtual

Live webcasts of select fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma^® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302385213.html

SOURCE REGENXBIO Inc.

FAQ

What investor conferences will RGNX attend in March 2025?

RGNX will attend four conferences in March 2025: TD Cowen Health Care (Boston), Leerink Partners Global Healthcare (Miami), Barclays Global Healthcare (Miami), and UBS Virtual CNS Day.

How long will RGNX conference webcasts be available for replay?

Webcasts of select fireside chats will be available for approximately 30 days following each presentation on REGENXBIO's website.

Which RGNX investor presentations will be virtual in 2025?

Two presentations will be virtual: the UBS Virtual CNS Day on March 17 and the RBC Inaugural Virtual Ophthalmology Conference on April 3, 2025.

What is the schedule for RGNX's Miami conference presentations in March 2025?

In Miami, RGNX will present at Leerink Partners Conference on March 11 at 9:20am ET and Barclays Conference on March 12 at 3:30pm ET.